Kampmann Melissa S. Has $4.59 Million Stake in Stryker Co. (NYSE:SYK)

Kampmann Melissa S. lessened its holdings in shares of Stryker Co. (NYSE:SYK) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,740 shares of the medical technology company’s stock after selling 1,425 shares during the quarter. Stryker accounts for approximately 3.6% of Kampmann Melissa S.’s portfolio, making the stock its 7th largest position. Kampmann Melissa S.’s holdings in Stryker were worth $4,587,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter worth $25,000. Dunhill Financial LLC boosted its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in Stryker during the fourth quarter valued at about $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker during the fourth quarter valued at about $33,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $378.06 on Thursday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $383.99 and a two-hundred day simple moving average of $373.85. The firm has a market capitalization of $144.26 billion, a P/E ratio of 48.72, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 earnings per share. On average, equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker’s payout ratio is 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SYK shares. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Finally, Truist Financial increased their price objective on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.